Recce PharmaceuticalsRECEF 31 EV-to-FCF is -5.75 as of Jun. 27, 2026. GuruFocus rates RECEF with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 333 Biotechnology companies, Recce Pharmaceuticals ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Recce Pharmaceuticals's Enterprise Value is $86.95 Mil.
Recce Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-15.13 Mil. Therefore, Recce Pharmaceuticals's EV-to-FCF for today is -5.75.
The historical rank and industry rank for Recce Pharmaceuticals's EV-to-FCF or its related term are showing as below:
RECEF'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.47 Med: 0 Max: 0
Current: -5.47
RECEF's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs RECEF: -5.47
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Recce Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Recce Pharmaceuticals's share price for today is $0.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Recce Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.075.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Recce Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recce Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Recce Pharmaceuticals's EV-to-FCF falls into.
Recce Pharmaceuticals's current Enterprise Value is $86.95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Recce Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-15.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recce Pharmaceuticals (RECEF) has a EV-to-FCF of -5.75 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Recce Pharmaceuticals and its competitors. According to the industry distribution chart, Recce Pharmaceuticals ranks #999999 out of 333 companies in the Biotechnology industry.
Is Recce Pharmaceuticals' EV-to-FCF too high?
Recce Pharmaceuticals' current EV-to-FCF is -5.75. Based on the distribution chart, Recce Pharmaceuticals ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Recce Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Recce Pharmaceuticals ranks #999999 out of 333 companies for EV-to-FCF. This places Recce Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Recce Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recce Pharmaceuticals's current EV-to-FCF is -5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (RECEF) has a current EV-to-FCF of -5.75. The current EV-to-FCF is -5.75. Recce Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Recce Pharmaceuticals (RECEF), the current EV-to-FCF is -5.75 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
31GF Score
Get the complete analysis for RECEF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RECEF has been successfully added to your 
